DrugPatentWatch Database Preview
Drugs in Development Information for Patritumab
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Patritumab?
Patritumab is an investigational drug.
There have been 5 clinical trials for Patritumab.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2014.
The most common disease conditions in clinical trials are Head and Neck Neoplasms, Carcinoma, Squamous Cell, and Neoplasms by Site. The leading clinical trial sponsors are Daiichi Sankyo Inc., QuantumLeap Healthcare Collaborative, and Covance.
There are six US patents protecting this investigational drug and one hundred and sixty-seven international patents.
Summary for Patritumab
| US Patents | 6 |
| International Patents | 167 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2014-03-01) |
| Vendors | 0 |
Recent Clinical Trials for Patritumab
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck | Covance | Phase 2 |
| A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck | Daiichi Sankyo Inc. | Phase 2 |
| A Study Using Patritumab in Combination With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer | Daiichi Sankyo Inc. | Phase 1 |
Clinical Trial Summary for Patritumab
Top disease conditions for Patritumab
Top clinical trial sponsors for Patritumab
US Patents for Patritumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Patritumab | Start Trial | Multispecific constructs | AbbVie Stemcentrx LLC (North Chicago, IL) | Start Trial |
| Patritumab | Start Trial | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein | CureVac AG (Tubingen, DE) | Start Trial |
| Patritumab | Start Trial | P97 fragments with transfer activity | biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) | Start Trial |
| Patritumab | Start Trial | Fragments of p97 and uses thereof | biOasis Technologies, Inc. (Richmond, CA) | Start Trial |
| Patritumab | Start Trial | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein | CureVac AG (Tubingen, DE) | Start Trial |
| Patritumab | Start Trial | Anti-CD324 monoclonal antibodies and uses thereof | ABBVIE STEMCENTRX LLC (North Chicago, IL) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Patritumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Patritumab | Canada | 2900764 | 2033-02-08 | Start Trial |
| Patritumab | European Patent Office | 2954056 | 2033-02-08 | Start Trial |
| Patritumab | Hong Kong | 1218930 | 2033-02-08 | Start Trial |
| Patritumab | Japan | 2016509014 | 2033-02-08 | Start Trial |
| Patritumab | World Intellectual Property Organization (WIPO) | 2014124326 | 2033-02-08 | Start Trial |
| Patritumab | Australia | 2013220749 | 2032-02-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
